摘要
目的探讨大剂量托瑞米芬增敏长春瑞滨和顺铂(NP方案)对非小细胞肺癌(NSCLC)的化疗及逆转肺癌多药耐药的效果。方法入组患者随机分为两组。治疗组采用大剂量托瑞米芬+NP方案治疗。对照组仅用NP方案治疗。治疗组患者在口服托瑞米芬后第2天和第8天抽血测定托瑞米芬血清浓度。结果治疗组PR 8例,SD 14例,PD 2例,有效率为33.3%。对照组PR 2例,SD19例,PD 3例,有效率为8.3%。治疗组与对照组相比,有效率差异有显著性(P<0.05)。治疗组中位生存期9.4个月,对照组为6.3个月,两组中位生存期差异有显著性(P<0.05)。治疗组1年生存率41.7%,对照组为20.8%,两组差异无显著性(P>0.05)。两组不良反应差异无显著性。托瑞米芬血清浓度在第2天和第8天均超过5μmol/L。结论通过随机对照研究证实,大剂量托瑞米芬能增敏长春瑞滨和顺铂对NSCLC的化疗及逆转肺癌多药耐药,联合NP方案治疗NSCLC安全有效。
Objective To investigate the efficacy of high-dose toremifene in reversing multidrug resistance and enhancing chemosensitivity of NSCLC. Methods Advanced NSCLC patients were divided into 2 groups randomly. The treatment group was given high-dose toremifene plus NP chemotherapy. The control group was given NP chemotherapy only. Plasma level of toremifene in the treatment group was measured on the second day and the eighth day after using toremifene. Results There were PR 8 ,SD 14 and PD 2 in the treatment group and the response rate was 33.3%. In the control group, there were PR 2,SD 19 and PD 3 and the response rate was 8. 3%. The difference between the response rates of the two groups was significant （P 〈 0. 05）. The median survival time was 9. 4 months and 6. 3 months respectively in the treatment group and in the control group. The difference in the median survival time between the two groups was significant （P 〈0. 05）. The rate of one-year survival rate was 41.7% and 20. 8% respectively in the treatment group and in the control group. The difference in the rate of one-year survival rate between the two groups was not significant（P 〉 0. 05 ）. The toxicity between the two groups was not significantly different. Plasma level of toremifene was over 5μmol/L on the second day and the eighth day. Conclusions The clinical study indicates that high-dose toremifene can reverse multidrug resistance to and enhance chemosensitivity of cisplatin and vinorelbine in NSCLC. Toremifene plus NP regimen is safe and effective in the treatment of NSCLC.
出处
《中国肿瘤临床与康复》
2009年第1期36-38,共3页
Chinese Journal of Clinical Oncology and Rehabilitation
基金
湖南省医药卫生科研计划课题(B2004-150)
关键词
肺肿瘤
托瑞米芬
长春瑞滨
顺铂
多药耐药
Lung neoplasms
Toremifene
Vinorelbine
Cisplatin
Multidrug resistance
